Journal
JOURNAL OF CANCER
Volume 8, Issue 3, Pages 410-416Publisher
IVYSPRING INT PUBL
DOI: 10.7150/jca.17144
Keywords
nivolumab; programmed death-1 inhibitor; targeted immunotherapy
Categories
Funding
- National Nature Science Foundation of the People's Republic of China [81370673]
- Key Medical Projects of Jiangsu Province [BL2014078]
- Key Discipline of Jiangsu Province
Ask authors/readers for more resources
Targeted immunotherapy has become the most promising approach for tumor patients. Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, can reverse immune suppression and release T cell activation. Nivolumab, a fully human immunoglobulin G4 PD-1 immune checkpoint inhibitor antibody, blocks PD-1 and promotes antitumor immunity, and it is effective for treating non-small-cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC) and other cancers. The present review summarizes the efficacy and current status of clinical trials of nivolumab and that enabled nivolumab to be investigated in patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available